UBC has a world-class reputation for its commercialization activities, and the Michael Smith Laboratories is proud to be part of this recognized success. One of the university's most successful spin-off companies, Neuromed Pharmaceuticals (now Zalicus) started in the research laboratory of Dr. Terry Snutch. In 2006 Neuromed Pharmaceuticals entered into an almost half-a-billion dollar agreement with Merck & Co. in what was the largest licensing deal in Canada's biotech history. Research in the Michael Smith Laboratories is helping to transform promising science into product-driven deals.
|1992||Biomarin Pharmaceuticals (note: formerly Synapse Technologies)|
|1995||Neuromed Technologies (acquired by Zalicus)|
|1998||Raven Biotech. Inc.|
|2000||TapImmune (formerly GeneMax Pharmaceuticals Inc.)|
|2002||Inimex Pharmaceuticals Inc.|